Re-EMBARC: Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

Sponsor

University of Texas at Austin (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05892744

Collaborator

Lehigh University (Other)

Enrollment

Location

Arm

Anticipated Duration (Months)

1.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.

Condition or Disease	Intervention/Treatment	Phase
Major Depressive Disorder Chronic Major Depression, Recurrent	Drug: Sertraline	Phase 4

Detailed Description

Our prior published studies found that sertraline outcome was predicted by biomarkers, primarily in frontoparietal control (FPCN), default mode (DMN), and ventral attention networks (VAN), from different single-modality neuroimaging data, including fMRI activation during emotional conflict regulation (Fonzo et al., 2019), resting EEG power signature (Rolle et al. 2020), and resting fMRI connectivity (Chin Fatt et al., 2020). Our recent study with resting EEG connectivity defined two sertraline-predictive subtypes that showed convergent validity between EEG and fMRI (Zhang et al., 2021). Therefore, we hypothesize that modality-specific regional activity/connections in these networks exhibit similar subject-wise covariation that will jointly predict sertraline treatment response more precisely than either modality alone. However, the derivation of multimodal biomarkers remains highly challenging and underexplored for treatment selection in depression. The overall objective of this proposal is to establish multimodal brain biomarkers using data-driven analytics for treatment selection in depression. With multimodal data from EMBARC, a large publicly-available dataset, we will devise advanced machine learning models to probe brain biomarkers jointly from multiple feature modalities including resting connectivity, task fMRI activation, and EEG band power. An independent cohort will be collected at Dell Medical School, The University of Texas at Austin (UT Austin) with methodology matching that utilized in the EMBARC study to produce a new sample of participants with independent data to validate these biomarker findings. To this end, we will utilize an integrative analysis of both fMRI and EEG to: 1) identify moderators of sertraline versus placebo response in MDD; 2) quantify brain signatures that predict antidepressant treatment outcome; 3) recruit 50 depressed patients, non-invasively assess brain function with a combination of task and resting state fMRI and EEG prior to treatment initiation, administer/prescribe the common antidepressant medication, sertraline (tradename Zoloft), track symptom response over time, and utilize these data as an independent new cohort to optimize and validate brain biomarkers.

Aim 1: Identify multimodal brain moderators of antidepressant treatment effects of sertraline medication in major depressive disorder (MDD) using an existing, publicly-available database (EMBARC). Task 1.1: Using the EMBARC dataset, we will design a canonical correlation analysis-based method to integrate fMRI and EEG to extract region-wise combined brain features. Task 1.2: We will use linear mixed-effect models in a full intent-to-treat framework with the combined features to identify moderators of sertraline versus placebo. Task 1.3: We will compare the statistical strength of the moderators identified between using multimodal features and each single-modality features, reveal neurobiological mechanisms underlying the multimodal moderators, and interpret their associations with depression-relevant clinical symptoms. This aim is crucial to establish novel multimodal brain moderators that can guide treatment selection in depression from a group-level perspective.

Aim 2: Quantify multimodal brain signatures that predict individual antidepressant treatment response to sertraline treatment in MDD using an existing, publicly-available database. Task 2.1: We will characterize multimodal brain signatures predictive of individual treatment outcomes using a machine learning tool that incorporates predictive modeling into our well-established latent space model with subtype guidance defined in our prior study. Task 2.2: We will compare multimodal signatures with single-modality and non-biological factors to confirm their efficacy in treatment outcome prediction and demonstrate their transferability to using EEG alone in clinical practice. Task 2.3: We will investigate which brain regions/connections of different modalities are most critical to delineating the multimodal signatures by examining their associations with single-modality features, and interpret the neurocircuitry models in depression underlying the treatment response. These tasks are necessary for developing multimodal signatures of individual responses to antidepressant treatment for personalized medicine.

Aim 3: Optimize and validate multimodal brain biomarkers using new data collected in an independent, open-label clinical trial of sertraline treatment for MDD. Task 3.1: We will recruit 50 individuals with MDD as an independent cohort and will adopt the EMBARC protocol design, including fMRI and EEG assessments at baseline followed by sertraline prescribed to these patients with clinical assessment of outcomes over 8 weeks. Task 3.2: We will refine the multimodal brain signatures using an adaptive optimization strategy with the samples collected each year. Task 3.3: We will perform an extensive validation using the new cohort to verify the multimodal biomarkers discovered in Aims 1-2. This aim will optimize our biomarker findings and provide strong evidence for their generalizability and reproducibility.

This project will establish informative multimodal biomarkers that can moderate clinical effects and predict individual responses to sertraline treatment, thereby providing a promising new avenue towards one of the first implementations in psychiatry of an objective test to inform treatment selection decisions. Our central hypothesis is that modality-specific regional brain activity/connections in FPCN, DMN, and VAN exhibit similar subject-wise covariation that can jointly predict sertraline treatment response more precisely than either modality alone.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

50 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

Open-label, single-arm treatmentOpen-label, single-arm treatment

Masking:

None (Open Label)

Primary Purpose:

Other

Official Title:

Establishing Multimodal Brain Biomarkers Using Data-driven Analytics for Treatment Selection in Depression

Anticipated Study Start Date :

Aug 1, 2023

Anticipated Primary Completion Date :

Jun 1, 2026

Anticipated Study Completion Date :

Aug 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Other: Sertraline hydrochloride, up to 200mg/day or maximum tolerable dose Established FDA-approved treatment for major depressive disorder	Drug: Sertraline 50-200mg/day Other Names: Zoloft

Arm

Intervention/Treatment

Other: Sertraline hydrochloride, up to 200mg/day or maximum tolerable dose

Established FDA-approved treatment for major depressive disorder

Drug: Sertraline

50-200mg/day

Other Names:

Zoloft

Outcome Measures

Primary Outcome Measures

Change from Baseline on the GRID Hamilton Depression Rating Scale (GRID-HAM-D) at 8 weeks [8 weeks]
Standardized clinician-administered measure of depression symptom severity

Secondary Outcome Measures

Change from Baseline on the Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR) at 8 weeks [8 weeks]
Self-report measure of depressive symptom severity
Change from Baseline on the Columbia-Suicide Severity Rating Scale (C-SSRS) at 8 weeks [8 weeks]
Clinician-administered measure of suicidal ideation
Change from Baseline on the Beck Anxiety Inventory (BAI) at 8 weeks [8 weeks]
Self-report measure of anxiety symptom severity
Change from Baseline on the Spielberger State Trait Anxiety Inventory-Trait Form (STAI-T) at 8 weeks [8 weeks]
Self-report measure of trait anxiety
Change from baseline on the Anger Attacks Questionnaire (AAQ) at 8 weeks [8 weeks]
Self-report measure of anger outbursts
Change from baseline on the Irritability domain of the Concise Associated Symptom Tracking Scale-Self Report at 8 weeks [8 weeks]
Self-report measure of irritability
Change from baseline on the Snaith-Hamilton Pleasure Scale (SHAPS) at 8 weeks [8 weeks]
Self-report measure of anhedonia
Change from baseline on the Patient Health Questionnaire for depression (PHQ-9) at 8 weeks [8 weeks]
Self-report measure of depressive symptom severity
Change from baseline on the General Anxiety Disorder (GAD-7) at 8 weeks [8 weeks]
Self-report measure of generalized anxiety disorder symptoms
Change from baseline on the Mood and Anxiety Symptom Questionnaire-30 at 8 weeks (MASQ-30) [8 weeks]
Self-report measure of general distress related to anxiety and depression
Change from baseline on the Standardized Assessment of Personality-Abbreviated Scale (SAPAS) at 8 weeks [8 weeks]
Assessment of personality
Change from baseline on the Clinical Global Impressions Scale (CGI) at 8 weeks [8 weeks]
Clinician-rated measure of global symptom severity

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

English as primary language, and comprehension suitable to understand experimenter instructions
Meet criteria for a current major depressive episode diagnosed through the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) (SCID-5)
Meet criteria for early onset (prior to age 30) of depression and either: a) current major depressive episode lasts for > 2 years; or b) participant meets criteria for recurrent major depression as evidenced by 2 or more major depressive episodes (including current episode) in their lifetime. These criteria will be assessed by the SCID-5.
Have a Quick Inventory of Depression Symptomology Self-Report Measures (QIDS) score > 14 at baseline and the week prior to first Sertraline administration
Willing and able to undergo MRI and EEG procedures.

Exclusion Criteria:

Non-early onset (i.e., after age 30), non-chronic (current episode lasting less than 2 years or only one lifetime major depressive episode, including current episode) qualifying Major Depressive Disorder
Must not have failed to respond to any prior antidepressant treatment in the current episode of sufficient duration and dose as defined by the Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire
Currently pregnant, planning to become pregnant, or breastfeeding
Evidence of current or prior history of psychosis or bipolar disorder as evidenced by self-report or clinical interview
Meeting DSM-5 criteria for a substance-use disorder of moderate or greater severity in the past 6 months
Unstable psychiatric or medical conditions that may require hospitalizations or contraindicate study medication (i.e. autism spectrum disorder, schizophrenia, cancer, congestive heart failure, etc.)
Contraindications to MRI including, but not limited to, history of stroke, brain tumors, brain hemorrhages, internal wires, electrodes, pacemakers, implants, irremovable ferromagnetic objects in head that are unsafe for MRI and/or cause large distortions in imaging data, etc.
History of epilepsy, moderate or severe traumatic brain injury, penetrating head injury, brain surgery, brain tumors, or any condition requiring an anticonvulsant
Treatment with electroconvulsive therapy, vagus nerve stimulation, or transcranial magnetic stimulation during the current depressive episode
Concomitant medication use that are likely to interfere or obscure effects from the study medication, including but not limited to antipsychotics and mood stabilizers
Current regular depression-specific evidence-based psychotherapy treatment
Considered by the investigative team to be a significant suicide risk as evidence by self-report or clinical interview